• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Resection post-radio-embolization in patients with single large hepatocellular carcinoma.单个大肝细胞癌患者的放射栓塞后切除术
Hepatobiliary Surg Nutr. 2024 Apr 3;13(2):307-310. doi: 10.21037/hbsn-24-3. Epub 2024 Mar 26.
2
Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.适合经动脉栓塞术的肝细胞癌患者的经动脉治疗：一项美国成本效益分析。
J Med Econ. 2023 Jan-Dec;26(1):1061-1071. doi: 10.1080/13696998.2023.2248840.
3
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.肝细胞癌经动脉降期治疗的比较分析：化疗栓塞与放射性栓塞
Am J Transplant. 2009 Aug;9(8):1920-8. doi: 10.1111/j.1600-6143.2009.02695.x. Epub 2009 Jun 22.
4
Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis.为肝细胞癌选择合适的降期和桥接治疗：经动脉放射性栓塞的作用是什么？一项汇总分析。
Cancers (Basel). 2023 Apr 2;15(7):2122. doi: 10.3390/cancers15072122.
5
Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma.钇[90Y]放射性微球动脉内放射栓塞后行肝移植或切除术治疗不可切除肝细胞癌的可行性和安全性。
HPB (Oxford). 2019 Nov;21(11):1497-1504. doi: 10.1016/j.hpb.2019.03.360. Epub 2019 Apr 17.
6
Radioembolization for hepatocellular carcinoma: what clinicians need to know.肝细胞癌的放射性栓塞治疗：临床医生需要了解的内容。
J Liver Cancer. 2022 Mar;22(1):4-13. doi: 10.17998/jlc.2022.01.16. Epub 2022 Feb 23.
7
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.经动脉放射性栓塞与阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌：生活质量恶化时间的匹配调整间接比较。
Adv Ther. 2022 May;39(5):2035-2051. doi: 10.1007/s12325-022-02099-0. Epub 2022 Mar 12.
8
Radioembolization for the treatment of hepatocellular carcinoma.放射性栓塞治疗肝细胞癌。
Clin Mol Hepatol. 2017 Jun;23(2):109-114. doi: 10.3350/cmh.2017.0004. Epub 2017 May 10.
9
Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.钇-90经动脉放射性栓塞治疗肝细胞癌
Adv Ther. 2016 May;33(5):699-714. doi: 10.1007/s12325-016-0324-7. Epub 2016 Apr 2.
10
[Transarterial radioembolization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma].[肝细胞癌和肝内胆管癌的经动脉放射性栓塞术]
Radiologe. 2022 Mar;62(3):234-238. doi: 10.1007/s00117-022-00974-z. Epub 2022 Feb 16.

引用本文的文献

1
Development and validation of a nomogram to predict cancer-specific survival of patients with large hepatocellular carcinoma accepting surgical resection: a real-world analysis based on the SEER database.预测接受手术切除的大肝细胞癌患者癌症特异性生存的列线图的开发与验证：基于监测、流行病学和最终结果（SEER）数据库的真实世界分析
J Gastrointest Oncol. 2024 Aug 31;15(4):1657-1673. doi: 10.21037/jgo-24-285. Epub 2024 Aug 20.

本文引用的文献

1
Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌患者转化治疗的临床特征与结局
Cancers (Basel). 2023 Oct 30;15(21):5221. doi: 10.3390/cancers15215221.
2
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.阿替利珠单抗联合贝伐珠单抗对比主动监测用于治疗接受手术切除或消融治疗的高风险肝细胞癌患者（IMbrave050）：一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20.
3
Resection Postradioembolization in Patients With Single Large Hepatocellular Carcinoma.经动脉化疗栓塞术后单发大肝癌切除术。
Ann Surg. 2023 Nov 1;278(5):756-762. doi: 10.1097/SLA.0000000000006061. Epub 2023 Aug 4.
4
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.酪氨酸激酶抑制剂联合抗 PD-1 抗体治疗后行肝切除术治疗不可切除肝细胞癌患者。
Ann Surg Oncol. 2023 May;30(5):2782-2790. doi: 10.1245/s10434-022-12530-z. Epub 2022 Sep 30.
5
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗序贯根治性转化（ABC转化）用于不可切除、不适合经动脉化疗栓塞术的中期肝细胞癌患者
Liver Cancer. 2022 Jul 27;11(5):399-406. doi: 10.1159/000526163. eCollection 2022 Sep.
6
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.使用特瑞普利单抗、仑伐替尼联合 TACE 治疗初始不可切除肝细胞癌的转化治疗：真实世界研究。
BJS Open. 2022 Sep 2;6(5). doi: 10.1093/bjsopen/zrac114.
7
Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial.钇 90 微球放射栓塞与载药微球化疗栓塞治疗不可切除肝细胞肝癌：TRACE Ⅱ 期随机对照试验结果。
Radiology. 2022 Jun;303(3):699-710. doi: 10.1148/radiol.211806. Epub 2022 Mar 8.
8
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.可切除肝细胞癌中围手术期纳武单抗单药治疗与纳武单抗联合伊匹单抗治疗的随机、开放标签、2 期临床试验。
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20.
9
Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group.经肝动脉化疗栓塞（TACE）治疗后的肝癌患者行手术切除的转化治疗：多学科工作组的建议。
HPB (Oxford). 2022 Jul;24(7):1007-1018. doi: 10.1016/j.hpb.2021.12.013. Epub 2021 Dec 25.
10
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.

Resection post-radio-embolization in patients with single large hepatocellular carcinoma.

作者信息

Hakkakian Kevin, Golse Nicolas

机构信息

Centre Hépato-Biliaire, Hôpital Paul-Brousse, Assistance Publique Hôpitaux de Paris, Villejuif, France.

Université Paris-Saclay, UMRS 1193, Physiopathogénèse et Traitement des Maladies du Foie, FHU Hepatinov, Villejuif, France.

出版信息

Hepatobiliary Surg Nutr. 2024 Apr 3;13(2):307-310. doi: 10.21037/hbsn-24-3. Epub 2024 Mar 26.

DOI:10.21037/hbsn-24-3
PMID:38617477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11007340/
Abstract
摘要